0001264124-12-000099.txt : 20120307
0001264124-12-000099.hdr.sgml : 20120307
20120307180417
ACCESSION NUMBER: 0001264124-12-000099
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120306
FILED AS OF DATE: 20120307
DATE AS OF CHANGE: 20120307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KOLTERMAN ORVILLE G
CENTRAL INDEX KEY: 0001236394
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19700
FILM NUMBER: 12675334
MAIL ADDRESS:
STREET 1: AMYLIN PHARMACEUTICALS INC
STREET 2: 9360 TOWNE CENTRE DR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000881464
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330266089
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9360 TOWNE CENTRE DR
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 6195522200
MAIL ADDRESS:
STREET 1: 9360 TOWNE CENTRE DR
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0304
4
2012-03-06
0
0000881464
AMYLIN PHARMACEUTICALS INC
AMLN
0001236394
KOLTERMAN ORVILLE G
9360 TOWNE CENTRE DR
SAN DIEGO
CA
92121
0
1
0
1
SVP, Chief Medical Officer
SVP, Chief Medical Officer
Common Stock
2012-03-06
4
A
0
10000
0
A
184276.9
D
Common Stock
2012-03-06
4
A
0
1529.3
0
A
7974.4
I
by ESOP
Common Stock
12767.3
I
Indirect-401k
Incentive Stock Option (right to buy)
16.02
2012-03-06
4
A
0
7901
0
A
2019-03-06
Common Stock
7901
7901
D
Non-Qualified Stock Option (right to buy)
16.02
2012-03-06
4
A
0
42099
0
A
2019-03-06
Common Stock
42099
42099
D
Represents a restricted stock unit award that vests in three equal annual installments from the date of grant. Restricted stock units are generally settled in shares of common stock of the company on the vesting date.
These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment.
25% of shares vest one year from the date of grant and the remainder vest in three equal annual installments becoming fully vested four years from the date of grant.
By: /s/ James R. Oehler, Attorney-in-Fact For: Orville G. Kolterman
2012-03-07